Anaemia after renal transplantation--role of immunosuppressive drugs and a pathophysiological appraisal.
Improvements in patient care and longevity on dialysis programmes together with the increased numbers of patients referred for renal replacement therapy will inevitably result in enlarging numbers of subjects with functioning renal transplants. While this translates to a boon for the patients in terms of survival and quality of life, a very real problem has begun to emerge, that of post-transplantation anaemia (PTA). The prevalence of this condition has been estimated by several studies as varying somewhere between one third and two thirds of all patients, with the same attendant problems as anaemia in the context of chronic kidney disease. PTA is multifactorial in origin and involves interplay between a number of risk factors, not least of all the immunosuppressive protocol. It is the purpose of this article to briefly review the contribution from transplant immunosuppression to PTA and to assess its likely effects on and treatment options for patients.
Goldsmith
David
D
Department of Nephrology and Transplantation, Guy's Hospital, London, UK. david.goldsmith@gstt.nhs.uk
Al-Khoury
Salam
S
Shah
Nilesh
N
Covic
Adrian
A
D000740:Anemia / Q000139:chemically induced* / Q000517:prevention & control*; D000818:Animals; D006084:Graft Rejection / Q000517:prevention & control*; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000009:adverse effects*; D018570:Risk Assessment / Q000379:methods*; D012307:Risk Factors
D007166:Immunosuppressive Agents